Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients who have completed the entire treatment period of the 28-week core study
Patients must be able to understand and communicate with the investigator and comply with the requirements for the study and must give a written, signed, and dated informed consent before study treatment in the extension study
You may not be if
Inability or unwillingness to undergo repeated subcutaneous injections
Inability to comply with study or follow-up procedures
Any medical or psychiatric condition which, in the investigator's opinion would preclude the participant from adhering to the protocol or completing the study per protocol
Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (\> 5 mIU/mL)
Women of childbearing potential (WoCBP), defined as all women physiologically capable of becoming pregnant, UNLESS
They are using simultaneously double barrier or two acceptable methods of contraception
They are postmenopausal with an appropriate clinical profile and had no regular menstrual bleeding for at least twelve (12) months prior to initial dosing
They have undergone reliable surgical sterilization at least six (6) months prior to initial dosing
Their career, lifestyle, or sexual orientation precludes intercourse with a male partner
Partners have been sterilized by vasectomy or other reliable means